Scorpius Ventures

Innovation shouldn't have to wait on funding

Too many promising biologic candidates are stalled without critical early-stage funding. Grant funding often falls short of the capital needed for pre-clinical and phase 1 manufacturing, but dilutive capital is hard to secure without positive early-stage data.

Scorpius Ventures offers a hybrid model for capital-efficient access to cGMP manufacturing, process development, and analytical services for early-stage biotechs through in-kind equity investment.

A bold step in onshoring American-made biologics

Collaborate with a U.S.-owned, U.S.-operated, and U.S.-financed biologics CDMO
Leverage Scorpius' expertise in drug substance manufacturing to assist with additional fundraising for continued clinical development
Flexible program supporting both mammalian and microbial programs

About Scorpius

Scorpius BioManufacturing is a U.S. biologics CDMO providing cGMP manufacturing services for protein modalities. Our facility in San Antonio, Texas specializes in working with emerging biotechs and academic researchers. Clients benefit from decades of expertise taking large molecule drugs to market and can rely on Scorpius to offer: Quality, Speed, Flexibility, & Responsiveness. Our capabilities include:

Up to 500-L scale for mammalian-based products
Up to 200-L scale for microbial-based products
On-site process and analytical development

What's next?

Submit our interest form. Scorpius will contact potential partners for Scorpius Ventures on a rolling basis.